These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Melanoma of unknown primary origin: a population-based study in the Netherlands. de Waal AC; Aben KK; van Rossum MM; Kiemeney LA Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553 [TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Galliot-Repkat C; Cailliod R; Trost O; Danino A; Collet E; Lambert D; Vabres P; Dalac S Eur J Surg Oncol; 2006 Sep; 32(7):790-4. PubMed ID: 16822643 [TBL] [Abstract][Full Text] [Related]
8. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755 [TBL] [Abstract][Full Text] [Related]
9. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Ballo MT; Garden AS; Myers JN; Lee JE; Diaz EM; Sturgis EM; Morrison WH; Gershenwald JE; Ross MI; Weber RS; Ang KK Head Neck; 2005 Aug; 27(8):718-21. PubMed ID: 15952196 [TBL] [Abstract][Full Text] [Related]
10. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346 [TBL] [Abstract][Full Text] [Related]
11. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Nowecki ZI; Rutkowski P; Michej W Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535 [TBL] [Abstract][Full Text] [Related]
12. Surgery with complete resection improves survival in radiooncologically treated patients with cervical lymph node metastases from cancer of unknown primary. Hauswald H; Lindel K; Rochet N; Debus J; Harms W Strahlenther Onkol; 2008 Mar; 184(3):150-6. PubMed ID: 18330511 [TBL] [Abstract][Full Text] [Related]
13. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144 [TBL] [Abstract][Full Text] [Related]
14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related]
15. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. Berger AC; Fierro M; Kairys JC; Berd D; Sato T; Andrel J; Hyslop T; Mastrangelo MJ J Surg Oncol; 2012 Jan; 105(1):15-20. PubMed ID: 21815149 [TBL] [Abstract][Full Text] [Related]
16. The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node. Jakub JW; Huebner M; Shivers S; Nobo C; Puleo C; Harmsen WS; Reintgen DS Ann Surg Oncol; 2009 Aug; 16(8):2245-51. PubMed ID: 19517194 [TBL] [Abstract][Full Text] [Related]